In recent years, various techniques relating to cancer virotherapy involving the use of viruses in cancer therapy have been developed. Viruses used in such therapy include vaccinia virus, as well as adenovirus and retrovirus.
In recent years, vaccinia virus has also been used as a multivalent vaccine for infections (HIV or SARS) in the form of an expression vector into which a foreign gene has been introduced, since the vaccinia virus has properties such as a wide range of hosts and high expression efficiency.
Moreover, a technique of utilizing the dissolving ability of vaccinia virus on cancer cells, so that the vaccinia virus can be utilized in cancer therapy, has been reported (see Patent Literature 1 and Patent Literature 2).
UCA1 has been reported as a gene associated with tumorigenesis or embryogenesis (see Non Patent Literature 1 to Non Patent Literature 4). It has been reported that a UCA1 (Urothelial cancer associated 1) gene is long-non coding RNA (lncRNA) that does not encode a protein, and that this gene is used as a marker for bladder cancer and the like.